SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 1st, 2019 • Nanoviricides, Inc. • Services-commercial physical & biological research • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 27, 2019, between NanoViricides, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
UNDERWRITING AGREEMENT between NANOVIRICIDES, INC. and KINGSWOOD CAPITAL MARKETS, A DIVISION OF BENCHMARK INVESTMENTS INC., as Representative of the Several Underwriters NANOVIRICIDES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • July 13th, 2020 • Nanoviricides, Inc. • Services-commercial physical & biological research • New York
Kingswood Capital Markets, a division of Benchmark Investments, Inc. As Representative of the several Underwriters named on Schedule 1 attached hereto 71 Battery Place, Suite 625
PRE-FUNDED COMMON STOCK PURCHASE WARRANT NANOVIRICIDES, INC.Nanoviricides, Inc. • September 27th, 2019 • Services-commercial physical & biological research • New York
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from NanoViricides, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 22nd, 2020 • Nanoviricides, Inc. • Services-commercial physical & biological research • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 21, 2020, between NanoViricides, Inc. a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
NANOVIRICIDES, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementNanoviricides, Inc. • August 3rd, 2020 • Services-commercial physical & biological research • New York
EXHIBIT A Form of Representative’s Warrant AgreementNanoviricides, Inc. • September 27th, 2019 • Services-commercial physical & biological research
THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ____, 2020 [DATE THAT IS 180 DAYS FROM THE EFFECTIVE DATE (as defined below) (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(f)(2)(G)(i), prior to at 5:00 p.m. (New York time) on the date that is five (5) years following the Effective Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from NANOVIRICIDES, INC., a Delaware corporation (the “Company”), up to ______1 shares of Common Stock, par value $0.001 per share, of the Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 13th, 2013 • Nanoviricides, Inc. • Services-commercial physical & biological research • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 9, 2013, between NanoViricides, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT Nanoviricides, inc.Nanoviricides, Inc. • March 1st, 2019 • Services-commercial physical & biological research
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after August __, 2019 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August __, 2024 (the “Termination Date”) but not thereafter, to subscribe for and purchase from NanoViricides, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Chardan Capital Markets, LLCNanoviricides, Inc. • March 1st, 2019 • Services-commercial physical & biological research • New York
This letter (the “Agreement”) constitutes the agreement between Chardan Capital Markets, LLC (“Chardan”) (the “Placement Agent”) and Nanoviricides, Inc. (the “Company”), that Placement Agent shall serve as the exclusive placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities (the “Securities”) of the Company, including shares (the “Shares”) of the Company’s common stock, par value $.001 per share (the “Common Stock”) and warrants to purchase shares of Common Stock (the “Warrants”). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Placement Agent would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents execu
SHARES OF COMMON STOCK, _________ PRE-FUNDED WARRANTS (EXERCISABLE FOR _________ SHARES) AND _________ WARRANTS (EXERCISABLE FOR _________ SHARES) OF NANOVIRICIDES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 27th, 2019 • Nanoviricides, Inc. • Services-commercial physical & biological research • New York
The undersigned, NANOVIRICIDES, INC., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of NANOVIRICIDES, INC., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which MAXIM GROUP LLC is acting as representative to the several Underwriters (in such capacity, the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriters) on the terms and conditions set forth herein.
2,500,000 SHARES OF COMMON STOCK OF NANOVIRICIDES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • January 27th, 2020 • Nanoviricides, Inc. • Services-commercial physical & biological research • New York
The undersigned, NanoViricides, Inc., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as defined below) as being subsidiaries or affiliates of NanoViricides, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Aegis Capital Corp. (“Aegis”) is acting as representative to the several Underwriters (in such capacity, the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
NANOVIRICIDES, INC. DIRECTOR RETAINER AGREEMENTDirector Retainer Agreement • November 19th, 2020 • Nanoviricides, Inc. • Services-commercial physical & biological research • Connecticut
THIS DIRECTOR RETAINER AGREEMENT (“Agreement”) is entered into by and between NanoViricides, Inc., a Nevada corporation (“Corporation”) and Brian Zucker (“Director”) as of November __, 2020.
NANOVIRICIDES, INC. Common Stock (par value $0.00001 per share) At Market Issuance Sales AgreementCommon Stock • April 5th, 2024 • Nanoviricides, Inc. • Pharmaceutical preparations • New York
NanoViricides, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with EF Hutton LLC (the “Agent”) as follows:
COMMON STOCK PURCHASE WARRANT Nanoviricides, inc.Common Stock Purchase Warrant • January 28th, 2020 • Nanoviricides, Inc. • Services-commercial physical & biological research
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ______________________. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Exchange Date, subject to the availability of authorized shares of Common Stock, and on or prior to 5:00 p.m. (New York City time) on August 27, 2024 (the “Termination Date”) but not thereafter, to subscribe for and purchase from NanoViricides, Inc., a Nevada corporation (the “Company”), up to 173,611 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
ContractCommon Stock Purchase Warrant • September 27th, 2007 • Nanoviricides, Inc. • Services-commercial physical & biological research • Nevada
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO NANOVIRICIDES, INC., THAT SUCH REGISTRATION IS NOT REQUIRED.
EMPLOYMENT AGREEMENTEmployment Agreement • March 11th, 2010 • Nanoviricides, Inc. • Services-commercial physical & biological research • Connecticut
EMPLOYMENT AGREEMENT ("Agreement") dated as of March 1, 2010, between ANIL R. DIWAN, c/o Nanoviricides, Inc., 135 Wood St., Suite 205, West Haven, CT ("Employee"), and NanoViricides, Inc., a corporation with offices at 135 Wood St., Suite 205, West Haven, CT ("the Company").
EMPLOYMENT AGREEMENTEmployment Agreement • March 11th, 2010 • Nanoviricides, Inc. • Services-commercial physical & biological research
AGREEMENT dated March 1, 2010, between NanoViricides, Inc. ("Employer"), with its principal place of business at 135 Wood Street, Suite 205, West Haven, Connecticut, and Jayant Tatake (the "Employee"), c/o NanoViricides, Inc., 135 Wood Street, Suite 205, West Haven, Connecticut.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 2nd, 2012 • Nanoviricides, Inc. • Services-commercial physical & biological research • New York
This Securities Purchase Agreement (this “Agreement”), dated as of June 26, 2012, is made by and between NanoViricides, Inc., a Nevada corporation (the “Company”), and Seaside 88, LP, a Florida limited partnership (the “Purchaser”).
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • March 20th, 2007 • Nanoviricides, Inc. • Services-commercial physical & biological research
Amendment to License Agreement by and between TheraCour Pharma, Inc., ("Theracour") as Licensor, and NanoViricides, Inc., (“Nano”) as Licensee.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 3rd, 2011 • Nanoviricides, Inc. • Services-commercial physical & biological research • New York
This Securities Purchase Agreement (this “Agreement”), dated as of November 1, 2011, is made by and between NanoViricides, Inc., a Nevada corporation (the “Company”), and Seaside 88, LP, a Florida limited partnership (the “Purchaser”).
NANOVIRICIDES, INC.Investor Subscription Agreement • October 5th, 2009 • Nanoviricides, Inc. • Services-commercial physical & biological research • Nevada
INVESTOR SUBSCRIPTION AGREEMENT (the “Subscription Agreement”) dated _______________, 2009 between NANOVIRICIDES, INC., a publicly-owned Nevada corporation with principal offices at 135 Wood Street, West Haven, Connecticut 06516 (the "Company") and the person or persons executing this Subscription Agreement on the last page hereof (the “Subscriber”). All documents mentioned herein are incorporated by reference.
THERACOUR-NANOVIRICIDES ADDITIONAL LICENSE AGREEMENTTheracour-Nanoviricides Additional License Agreement • March 18th, 2010 • Nanoviricides, Inc. • Services-commercial physical & biological research • New York
This License Agreement (the "Agreement") is made between TheraCour Pharma, Inc. a Connecticut corporation (collectively referred to as "TheraCour" or “Theracour”) and NanoViricides, Inc., a Nevada corporation ("Nano").
NANOVIRICIDES, INC.Investor Subscription Agreement • November 14th, 2006 • Nanoviricides, Inc. • Nevada
INVESTOR SUBSCRIPTION AGREEMENT (the "Subscription Agreement") dated _______________, 2005 between NANOVIRICIDES, INC., a publicly-traded Nevada corporation with principal offices at 135 Wood Street, West Haven, Connecticut 06516 (the "Company") and the person or persons executing this Subscription Agreement on the last page hereof (the "Subscriber"). All documents mentioned herein are incorporated by reference.
NANOVIRICIDES, INC.Investor Subscription Agreement • August 29th, 2008 • Nanoviricides, Inc. • Services-commercial physical & biological research • Nevada
INVESTOR SUBSCRIPTION AGREEMENT (the "Subscription Agreement") dated _________, 2008 between NANOVIRICIDES, INC., a publicly-owned Nevada corporation with principal offices at 135 Wood Street, West Haven, Connecticut 06516 (the "Company") and the person or persons executing this Subscription Agreement on the last page hereof (the "Subscriber"). All documents mentioned herein are incorporated by reference.
NANOVIRICIDES, INC.Investorsubscription Agreement • October 18th, 2007 • Nanoviricides, Inc. • Services-commercial physical & biological research • Nevada
INVESTORSUBSCRIPTION AGREEMENT (the "Subscription Agreement") dated _________ __, 2007, between NANOVIRICIDES, INC., a Nevada corporation (the "Company") and the person or persons executing this Agreement on the last page (the "Subscriber"). All documents mentioned herein are incorporated by reference.
EMPLOYMENT AGREEMENTEmployment Agreement • July 23rd, 2018 • Nanoviricides, Inc. • Services-commercial physical & biological research • Connecticut
EMPLOYMENT AGREEMENT (“Agreement”) dated as of July 1, 2018, between ANIL R. DIWAN, c/o NanoViricides, Inc., 1 Controls Drive, Shelton, CT 06484 (“Employee”), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 (“the Company”).
AGREEMENTAgreement • December 23rd, 2019 • Nanoviricides, Inc. • Services-commercial physical & biological research
AGREEMENT dated May 31, 2013, between NanoViricides, Inc. ("NanoViricides"), with its principal place of business at 135 Wood Street, Suite 205, West Haven, Connecticut, and Meeta Vyas ("Vyas"), residing at 155 Parsonage Road. Greenwich, Connecticut.
ContractNanoviricides, Inc. • August 29th, 2008 • Services-commercial physical & biological research
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO NANOVIRICIDES, INC., THAT SUCH REGISTRATION IS NOT REQUIRED.
DEFERRED Expense EXCHANGE AGREEMENTDeferred Expense Exchange Agreement • December 19th, 2019 • Nanoviricides, Inc. • Services-commercial physical & biological research
This DEFERRED EXPENSE EXCHANGE AGREEMENT (this “Agreement”), is entered into as of December 17, 2019 (“Execution Date”), by and between NanoViricides, Inc., a Nevada corporation (the “Company”) and TheraCour Pharma, Inc., a Connecticut corporation (“TheraCour”) (collectively, the “Parties”).
LINE OF CREDIT AGREEMENTLine of Credit Agreement • February 16th, 2024 • Nanoviricides, Inc. • Pharmaceutical preparations • Connecticut
THIS LINE OF CREDIT AGREEMENT (“Agreement”) is made and entered into effective as of the 13th day of November, 2023 (“Effective Date”) by and among Anil R. Diwan and/or his successors and assigns (collectively, the “Lender”) and NanoViricides, Inc., a Delaware Corporation (the “Borrower”).
ContractCommon Stock Purchase • November 14th, 2006 • Nanoviricides, Inc. • Nevada
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO CERTIFIED SERVICES, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.
OPEN END MORTGAGE NOTEOpen End Mortgage Note • December 19th, 2019 • Nanoviricides, Inc. • Services-commercial physical & biological research • Connecticut
FOR VALUE RECEIVED, NANOVIRICIDES, INC. (the ''Borrower"), a Nevada corporation with a mailing address of 1 Controls Drive, Shelton, CT, 06484 promises to pay to the order of ANIL R. DIWAN, AN INDIVIDUAL having a principal address at __________________________ (the "Lender"), at such office or at such other place as the Lender may designate from time to time in writing, the principal sum of TWO MILLION AND 00/100 ($2,000,000.00) DOLLARS ("Loan") received from the Lender in two tranches of ONE MILLION AND 00/100 ($1,000,000.00) DOLLARS each pursuant to the terms of this Open End Mortgage Note ( “Note”) and the Open End Mortgage Deed of even date herewith ("Open End Mortgage") executed by the Borrower.
Mr. Anil Diwan Chairman and President Nanoviricides Inc.Nanoviricides, Inc. • May 22nd, 2020 • Services-commercial physical & biological research • New York
DEFERRED EXPENSE EXCHANGE AGREEMENTDeferred Expense Exchange Agreement • September 1st, 2023 • Nanoviricides, Inc. • Pharmaceutical preparations
This DEFERRED EXPENSE EXCHANGE AGREEMENT (this “Exchange Agreement”), effective of July 19, 2023 (“Execution Date”), by and between NanoViricides, Inc., a Nevada corporation (the “Company”) and TheraCour Pharma, Inc., a Connecticut corporation (“TheraCour”) (collectively, the “Parties”).
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • February 16th, 2024 • Nanoviricides, Inc. • Pharmaceutical preparations
This AMENDMENT TO LICENSE AGREEMENT (this “Amendment”), dated as of the 13 day of February, 2024 (the “Effective Date”), is entered into by TheraCour Pharma, Inc., a Connecticut corporation (“Licensor”) and NanoViricides, Inc., a Delaware corporation (the “Licensee”). Licensor and Licensee are each referred to herein individually as a “Party” and collectively as the “Parties.”
